To discover outcomes of patients treated with Rivaroxaban with atrial fibrillation with at least one additional investigator-determined risk factor for stroke in real-life practice.
- Observation: Cohort
- Perspective: Prospective
- Sampling: Probability Sample
Males and females aged 18 years and over
|Type||Measure||Time Frame||Safety Issue|
|Primary||To assess the rate of stroke and systemic embolisation in registry participants||2 years||No|